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Background: Epidemiologic evidence supports an inverse association between high-density lipoprotein cholesterol (HDL-C) and cardiovascular 
disease (CVD) risk. The NIH-funded AIM-HIGH study recently evaluated the effects of the addition of niacin to background low-density lipoprotein 
cholesterol (LDL-C) lowering medications on CVD events in patients with atherosclerosis, and well-controlled LDL-C levels. AIM-HIGH was stopped 
early due to futility in mitigating CVD risk and a trend toward more strokes in the niacin arm. We sought to assess the impact of these results on the 
collective body of evidence evaluating the clinical efficacy of niacin.
Methods: Randomized controlled trials of niacin, alone or combined with other lipid altering therapy, were identified via MEDLINE. Pooled odds 
ratios for achieved endpoints of Coronary Heart Disease (CHD) and stroke were calculated using the Peto fixed effects model.
Results: 10 eligible trials including 9859 subjects were identified. CHD events were significantly less frequent in niacin treated patients (OR=0.8, 
p=0.0005; FIGURE). This finding persisted in analysis limited to ‘niacin-only’ trials. A trend toward decreased stroke risk was observed in niacin 
treated subjects (OR=0.82, p = 0.06).
Conclusion: While perhaps suggestive of limited benefit in select patients, the results of AIM-HIGH are insufficient to alter the aggregate 
perspective of available data supporting the use of niacin as an effective agent to reduce CHD risk.
 
